Paris-Trousseau syndrome

Paris-Trousseau syndrome is a rare genetic disorder characterized by a combination of bleeding disorders and bone marrow abnormalities. It is named after the French physicians who first described the condition. This syndrome is typically associated with a specific chromosomal abnormality involving the Fli-1 gene.

Presentation

Individuals with Paris-Trousseau syndrome often present with a range of symptoms, including:

• Thrombocytopenia (low platelet count)
• Abnormal platelet function
• Increased risk of bleeding
• Bone marrow abnormalities
• Developmental delays

Genetics

Paris-Trousseau syndrome is caused by a deletion on chromosome 11q23, which affects the Fli-1 gene. This gene plays a crucial role in the development and function of megakaryocytes, the cells responsible for producing platelets. The deletion leads to impaired platelet production and function, resulting in the bleeding tendencies observed in affected individuals.

Diagnosis

Diagnosis of Paris-Trousseau syndrome typically involves:

• Clinical evaluation of symptoms
• Blood tests to assess platelet count and function
• Bone marrow biopsy
• Genetic testing to identify the chromosomal deletion

Management

Management of Paris-Trousseau syndrome focuses on addressing the bleeding disorders and supporting overall health. This may include:

• Platelet transfusions
• Medications to enhance platelet function
• Regular monitoring of blood counts
• Supportive therapies for developmental delays

Prognosis

The prognosis for individuals with Paris-Trousseau syndrome varies depending on the severity of the symptoms and the effectiveness of the management strategies. With appropriate medical care, many individuals can lead relatively normal lives, although they may require ongoing medical support.

Related Pages

• Thrombocytopenia
• Bone marrow
• Chromosome 11
• Genetic disorders
• Platelet function